Expression of the human immunodeficiency virus type I pol open reading frame in Escherichia coli led to several protease-mediated processing steps of the pol precursor polyprotein. Accumulation of two polypeptides with molecular sizes of 64 and 52 kilodaltons, with which reverse transcriptase activity is associated, was observed. The protease moiety of the precursor polyprotein accumulated as a 10-kilodalton species as a result of two specific cleavages. Furthermore, a single-amino-acid substitution in the putative active site of protease totally abolished processing of the precursor polyprotein.
In the absence of a suitable vaccine, chemotherapy offers an alternative approach by which the immunodeficiency caused by human immunodeficiency virus (HIV) infection (8) can be arrested. Protease, reverse transcriptase, and endonuclease, the products of the pol open reading frame (9) , are critical enzymes against which it might be possible to develop an antiviral drug. These proteins are coordinately expressed as a precursor polyprotein from which, possibly through the pol-encoded protease, the individual components are released. Thus, drugs which inhibit protease may interrupt the life cycle of the virus. A better insight into protease action is however necessary. Since the pol open reading frame of HIV type I (HIV-I) has been expressed in Escherichia coli and Bacillus subtilis and leads to correctly processed reverse transcriptase polypeptides (3, 5, 10) , bacterial expression systems offer a suitable means to analyze the sequential events of pol polyprotein cleavage.
The synthesis and cleavage of the HIV-I pol precursor polyprotein in our E. coli expression system is illustrated (Fig. 1) . We (5) and other groups (3, 10) have demonstrated that two of the cleavage products are polypeptides with molecular sizes of 64 and 52 kilodaltons (kDa) with which reverse transcriptase activity is associated. Since protease is the first translation product of the pol open reading frame, we had expected our serum with HIV-I specific antibodies to detect this 18-kDa polypeptide. The inability to do so suggested either that protease was extremely labile in E. coli or that our serum had a low titer of the relevant antibodies. Amino acid sequence analysis (2, 6) suggested that the Phe-Pro bond between protease and reverse transcriptase is cleaved during processing. The Phe-Pro sequence which separates protease from reverse transcriptase also occurs within protease, suggesting that it might undergo a secondary internal cleavage after release from reverse transcriptase.
To determine whether the protease was internally cleaved, we repeated the experiment outlined in Fig. 1 fer to nitrocellulose (12) , immunoreactive polypeptides were determined by using three separate antibody preparations. These were (i) a pool of sera with HIV-I-specific antibodies, (ii) antibodies to a synthetic peptide spanning amino acids 39 through 62 of protease (peptide I), and (iii) antibodies to a synthetic peptide spanning amino acids 86 through 108 of protease (peptide II). These peptide sequences lie on either side of the internal Phe-Pro bond of protease (Fig. 2) . The results of this assay are shown (Fig. 3) .
By using sera with HIV-I-specific antibodies (Fig. 3A) predicted by the pol fragment in the expression vector pRTL10, which contains protease (18 kDa), reverse transcriptase (64 kDa), and the amino-terminal portion of endonuclease (10 kDa). With time, the precursor polypeptide disappeared, and polypeptides of 64 and 52 kDa were observed. Antibodies against protease peptide I (Fig. 3B) detected two forms of the precursor polyprotein and additional polypeptides with sizes between 19 and 7 kDa. These smaller-sized polypeptides appeared after 30 min of induction and were relatively labile. Probing the same samples with antibodies to protease peptide II (Fig. 3C ) revealed accumulation of a 10-kDa polypeptide. From the results obtained with antibodies to peptides I and II, it would indeed appear that full-length protease is released from the polyprotein but is subject almost simultaneously to a secondary internal cleavage to smaller polypeptides, one of which (the 10-kDa form) remains stable. Since peptides I and II lie on either side of the internal Phe-Pro bond, our results suggest that the internal cleavage occurs here. Internal cleavage of protease at this Phe-Pro bond predicts polypeptides of 7.8 and 10.8 kDa, strengthening the results illustrated in Fig. 3 .
To further elucidate the secondary cleavage of protease, we cloned the entire pol gene as a carboxy-terminal fusion to E. coli chloramphenicol acetyltransferase (CAT) (7) with the intention of stabilizing the labile protease cleavage product as an carboxy-terminal fusion to CAT (Fig. 4) . Probing fractionated cell proteins with sera with HIV-I-specific antibodies (Fig. 4A) revealed a large-size precursor polyprotein which would correspond to a fusion of CAT, protease, reverse transcriptase, and the entire endonuclease. With time, this precursor also disappeared and the 64-and 52-kDa reverse transcriptase-like polypeptides accumulated. In contrast to results from pRTL10, antibodies against protease (Fig.  4B) . This corresponds to the predicted size of full-length CAT plus the amino-proximal portion of protease released by internal cleavage. As further support of this result, no 7-kDa polypeptide was detected by the same antibodies. Probing with antibodies against protease peptide II (Fig. 4C ) illustrated, however, that the stable carboxy-proximal portion of protease is still released from the polyprotein. Finally, probing lysates with polyclonal CAT antibodies (Fig.  4D ) revealed a fusion protein 7 kDa larger than authentic CAT as well as some minor degradation products. The results shown in Fig. 4B and D are thus complementary, illustrating that the labile portion of protease has been stabilized as a carboxy-terminal fusion to CAT.
As proof that the 64-and 52-kDa polypeptides released from the polyproteins of pRTL10 and pRTL12 ( Fig. 3 and 4) are indeed reverse transcriptase, a partial enzyme purification from both recombinant clones was undertaken (5), the results of which are presented (Fig. 5 ). Immunological analysis with rabbit polyclonal antiserum against HIV-I reverse transcriptase revealed both molecular size forms (Fig. 5A) . Furthermore, reverse transcriptase activity can be detected in fractions which contain these polypeptides (Fig.  SB) . The possibility that this activity results from an E. coli enzyme was eliminated by performing a similar purification procedure on the parental E. coli strain, in which no activity could be recovered (data not shown).
One possibility our results have as not yet excluded is that E. coli proteases and not the HIV-I protease moiety are responsible for the processing of the precursor polyprotein. Sequence alignment of HIV-I protease and other retroviral proteases reveals a highly conserved stretch of amino acids with similarity to sequences around the active site of amino acids Asp-Thr-Pro of aspartyl proteases (4). As a consequence, we have substituted the Asp residue at the putative active site of HIV-I protease with Ala via oligonucleotidedirected mutagenesis (11) . The mutated protease was subsequently introduced into the context of the wild-type pol sequences in our E. coli expression system. In this case, isopropyl-,-D-thiogalactopyranoside induction leads to the accumulation of only the precursor polyprotein (Fig. 6) , suggesting that the protease-reverse transcriptase as well as reverse transcriptase-endonuclease cleavages are mediated by the HIV-I protease.
In conclusion, we have demonstrated in E. coli that release of protease from the HIV-I pol precursor polyprotein is a two-step event initiated by autocatalytic cleavage of the precursor through the protease moiety. A full-length form of the protease is released, followed by internal cleavage to a labile amino-proximal polypeptide and a stable 10-kDa carboxy-proximal polypeptide; recent studies indicate that the latter polypeptide retains catalytic activity (M. Graves, personal communication). Whether an analogous processing leads to such protease forms in vivo remains to be elucidated. Preliminary immunological analysis of semipurified virus particles with antibodies to protease peptides I and II reveals similar polypeptides as those found here in E. coli (S. F. J. Le Grice and J. Mous, unpublished data). However, final proof requires N-terminal amino acid sequence analysis of these polypeptides. Experiments of this nature are presently underway.
